Abstract
Recombinant expression of antibody molecules in mammalian cells offers important advantages over traditionally utilized bacterial expression, including glycosylation required for antibody functionality and markedly reduced levels of endotoxin contamination. Advances in transient mammalian expression systems enable high yields (>100 mg/liter) that now allow for effective recombinant antibody production at a reasonable cost. Here, we provide step-by-step protocols for the design and recombinant expression of full-length IgG antibodies and antibody-derived constructs (including Fab, Fc-fusions and bispecifics) in mammalian cells. Antibody constructs are designed by combining antibody variable domains, generated by phage display or derived from human/humanized monoclonals, with constant regions. The constructs are then expressed from mammalian vectors, secreted into culture media, purified by affinity chromatography and characterized by biolayer interferometry. This article provides detailed protocols, sequences and strategies that allow the expression and purification of endotoxin-free antibody reagents suitable for testing in animal models within a 3-week time frame.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Begley, C.G. & Ellis, L.M. Drug development: raise standards for preclinical cancer research. Nature 483, 531–533 (2012).
Bradbury, A. & Pluckthun, A. Reproducibility: standardize antibodies used in research. Nature 518, 27–29 (2015).
Rouet, R. et al. Expression of high-affinity human antibody fragments in bacteria. Nat. Protoc. 7, 364–373 (2012).
Beck, A. et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 9, 482–501 (2008).
Nose, M. & Wigzell, H. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80, 6632–6636 (1983).
Simmons, L.C. et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263, 133–147 (2002).
Wakelin, S.J. et al. “Dirty little secrets”—endotoxin contamination of recombinant proteins. Immunol. Lett. 106, 1–7 (2006).
Beutler, B. & Rietschel, E.T. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3, 169–176 (2003).
Schwarz, H., Schmittner, M., Duschl, A. & Horejs-Hoeck, J. Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells. PLoS ONE 9, e113840 (2014).
Wolff, S.M. Biological effects of bacterial endotoxins in man. J. Infect. Dis. 128, S259–S264 (1973).
Copeland, S. et al. Acute inflammatory response to endotoxin in mice and humans. Clin. Diagn. Lab. Immunol. 12, 60–67 (2005).
Frenzel, A., Hust, M. & Schirrmann, T. Expression of recombinant antibodies. Front. Immunol. 4, 217 (2013).
Brooks, S.A. Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins. Expert Rev. Proteomics 3, 345–359 (2006).
Dumont, J., Euwart, D., Mei, B., Estes, S. & Kshirsagar, R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit. Rev. Biotechnol. 36, 1110–1122 (2016).
Wurm, F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393–1398 (2004).
Dalton, A.C. & Barton, W.A. Over-expression of secreted proteins from mammalian cell lines. Protein Sci. 23, 517–525 (2014).
Chiou, H.C. et al. Scalable transient protein expression. Methods Mol. Biol. 1104, 35–55 (2014).
Liu, C.Y. et al. Attaining high transient titers in CHO cells. Genetic Eng. Biotechnol. News 35, 34–35 (2015).
Backliwal, G. et al. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 36, e96–e96 (2008).
Jones, M.B. et al. Mammalian transient transfection system. Genetic Eng. Biotechnol. News 32, 50–51 (2012).
Lee, C.M.Y., Iorno, N., Sierro, F. & Christ, D. Selection of human antibody fragments by phage display. Nat. Protoc. 2, 3001–3008 (2007).
Eisenstein, M. Living factories of the future. Nature 531, 401–403 (2016).
Peccoud, J. Synthetic Biology: Fostering the Cyber-Biological Revolution (Oxford University Press, 2016).
von Boehmer, L. et al. Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat. Protoc. 11, 1908–1923 (2016).
Dodev, T.S. et al. A tool kit for rapid cloning and expression of recombinant antibodies. Sci. Rep. 4, 5885 (2014).
Tiller, T., Busse, C.E. & Wardemann, H. Cloning and expression of murine Ig genes from single B cells. J. Immunol. Methods 350, 183–193 (2009).
Underhill, M.F., Smales, C.M., Naylor, L.H., Birch, J.R. & James, D.C. Transient gene expression levels from multigene expression vectors. Biotechnol. Prog. 23, 435–443 (2007).
Chng, J. et al. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells. mAbs 7, 403–412 (2015).
Hacker, D.L. et al. Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells. Protein Expr. Purif. 92, 67–76 (2013).
Geisse, S. Reflections on more than 10 years of TGE approaches. Protein Expr. Purif. 64, 99–107 (2009).
Baldi, L., Hacker, D.L., Meerschman, C. & Wurm, F.M. Large-scale transfection of mammalian cells. in Protein Expression in Mammalian Cells: Methods and Protocols 801, 13–26 (2012).
Lai, T., Yang, Y. & Ng, S.K. Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals 6, 579–603 (2013).
Ye, J. et al. Rapid protein production using CHO stable transfection pools. Biotechnol. Prog. 26, 1431–1437 (2010).
Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323–327 (1988).
Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522–525 (1986).
Clackson, T., Hoogenboom, H.R., Griffiths, A.D. & Winter, G. Making antibody fragments using phage display libraries. Nature 352, 624–628 (1991).
Jäger, V., Büssow, K. & Schirrmann, T. Transient recombinant protein expression in mammalian cells. in Animal Cell Culture 27–64 Springer, 2015).
Vazquez-Lombardi, R. et al. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells. Nat. Commun. 8, 15373 (2017).
Kontermann, R.E. Dual targeting strategies with bispecific antibodies. Mabs 4, 182–197 (2012).
GE-Healthcare. Recombinant Protein Purification: Principles and Methods (GE Healthcare Bio-Sciences AB, 2012).
Concepcion, J. et al. Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization. Comb. Chem. High Throughput Screen. 12, 791–800 (2009).
Vasu, S. et al. High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers. US Patent Application No. 13/886,226 (2013).
Chun, B.H., Park, S.Y., Chung, N. & Bang, W.G. Enhanced production of recombinant B-domain deleted factor VIII from Chinese hamster ovary cells by propionic and butyric acids. Biotechnol. Lett. 25, 315–319 (2003).
Fan, S. et al. Valproic acid enhances gene expression from viral gene transfer vectors. J. Virol. Methods 125, 23–33 (2005).
Rodrigo, G., Gruvegård, M. & Van Alstine, J.M. Antibody fragments and their purification by protein L affinity chromatography. Antibodies 4, 259–277 (2015).
Petsch, D. & Anspach, F.B. Endotoxin removal from protein solutions. J. Biotechnol. 76, 97–119 (2000).
Malyala, P. & Singh, M. Endotoxin limits in formulations for preclinical research. J. Pharm. Sci. 97, 2041–2044 (2008).
Dudgeon, K. et al. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc. Natl. Acad. Sci. USA 109, 10879–10884 (2012).
Haryadi, R. et al. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS ONE 10, e0116878 (2015).
Feige, M.J. et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol. Cell 34, 569–579 (2009).
Sadhu, C., Dutta, S. & Gopinathan, K.P. Influence of formamide on the thermal stability of DNA. J. Biosci. 6, 817–821 (1984).
Kozak, M. Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes. Proc. Natl. Acad. Sci. USA 87, 8301–8305 (1990).
Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Fields, C. et al. Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. Nat. Protoc. 8, 1125–1148 (2013).
Overdijk, M.B. et al. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189, 3430–3438 (2012).
Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu–positive metastatic breast cancer. J. Clin. Oncol. 26, 1789–1796 (2008).
Smith, P., DiLillo, D.J., Bournazos, S., Li, F. & Ravetch, J.V. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181–6186 (2012).
Walsh, N.C. et al. Humanized mouse models of clinical disease. Annu. Rev. Pathol.: Mech. Dis. 12, 187–215 (2017).
Acknowledgements
This work was supported by the Australian Research Council and the National Health and Medical Research Council.
Author information
Authors and Affiliations
Contributions
R.V.-L., D.N., A.L., P.S. and C.Z. wrote the manuscript and generated figures. D.C. wrote the manuscript, generated figures and supervised the research.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Data 1
Sequences for construct design. (PDF 391 kb)
Supplementary Data 2
Herceptin IgG heavy chain.dna. (ZIP 8 kb)
Supplementary Data 3
Herceptin IgG light chain.dna. (ZIP 5 kb)
Supplementary Data 4
Herceptin Fab heavy chain.dna. (ZIP 5 kb)
Supplementary Data 5
Herceptin Fab light chain.dna. (ZIP 5 kb)
Supplementary Data 6
IL-2-Fc.dna. (ZIP 8 kb)
Supplementary Data 7
Fc-His.dna. (ZIP 7 kb)
Supplementary Data 8
Herceptin-Erbitux bispecific scFv.dna. (ZIP 12 kb)
Rights and permissions
About this article
Cite this article
Vazquez-Lombardi, R., Nevoltris, D., Luthra, A. et al. Transient expression of human antibodies in mammalian cells. Nat Protoc 13, 99–117 (2018). https://doi.org/10.1038/nprot.2017.126
Published:
Issue Date:
DOI: https://doi.org/10.1038/nprot.2017.126
This article is cited by
-
Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
BMC Biology (2024)
-
A rapid cell-free expression and screening platform for antibody discovery
Nature Communications (2023)
-
Generation and characterization of genome-modified chondrocyte-like cells from the zebra finch cell line immortalized by c-MYC expression
Frontiers in Zoology (2022)
-
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy
Acta Neuropathologica Communications (2022)
-
Golden Gate assembly with a bi-directional promoter (GBid): A simple, scalable method for phage display Fab library creation
Scientific Reports (2020)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.